Specialised Therapeutics

Specialised Therapeutics is an international, independent pharmaceutical company providing specialist medicines to patients in Australia, New Zealand and across South East Asia. Founded in 2008 by international pharmaceutical executives Carlo Montagner and Bozena Zembrzuski, Specialised Therapeutics began with a single oncology product that is now one of the most successful branded chemotherapies ever commercialised in Australia. Since its inception, the ST product portfolio has expanded, now spanning oncology, haematology, neurology, supportive care, genomic assays and ophthalmology - although it is not confined to these therapy areas. ST is headquartered in Singapore, with representative offices in Australia and New Zealand. It partners with international biotech and pharmaceutical companies, expertly championing their products from pre-registration to full commercialisation in key AU, NZ and SE Asia regions. With extensive experience navigating complex regulatory and reimbursement pathways in diverse markets, it maintains a highly successful track record of commercialising specialty products. International Partners include. Incyte Biosciences International. Celgene (acquired by BMS). Puma Biotechnology. Helsinn Healthcare. photonamic GmbH. Ariad Pharmaceuticals (now Takeda Pharmaceuticals). Genomic Health Inc (now Exact Sciences). Alimera Sciences Inc. PharmaMar. Onconova Therapeutics